Original research
par
Gahrton, Caroline et al
Date de publication
2024
Géographie
Sweden
Langue de la ressource
English
Texte disponible en version intégrale
Oui
Open Access / OK to Reproduce
Oui
Évalué par des pairs
Yes
L’objectif
With the introduction of a needle syringe program (NSP) in Stockholm, Sweden and unrestricted availability of direct acting antiviral (DAA) treatment, we investigate the change of prevalence and incidence of HCV infection among people who inject drugs (PWID) over time.
Constatations/points à retenir
The prevalence of viremic HCV infection decreased from 62% to 30% year 2013-2021 while the prevalence of cured after treatment increased from 0 to 22%, corresponding to 42% cured after treatment out of those eligible in 2021.
La conception ou méthodologie de recherche
All persons attending the Stockholm Needle Syringe Program 2013-2021 (n=4,138) were included.
Mots clés
About PWUD
Harm reduction
Injecting drugs
Social benefits
